Literature DB >> 4027147

Immediate and long-term effects of nicardipine, at rest and during exercise, in patients with coronary artery disease.

C A Visser, W Jaarsma, G Kan, J J Koolen, K I Lie.   

Abstract

Haemodynamic effects of nicardipine were studied in 12 patients with documented coronary artery disease. Following nicardipine 10 mg, given intravenously to patients at rest, the heart rate increased, mean arterial pressure decreased, cardiac index increased, and systemic vascular resistance decreased significantly. Compared with the control exercise values, significant increases in heart rate and cardiac index and significant decreases in mean arterial pressure, systemic vascular resistance, and left ventricular end diastolic pressure occurred when nicardipine, 10 mg i.v., was given to the patients during exercise. All 12 patients complained of angina during the exercise phase, but following treatment with nicardipine, 10 mg i.v., only four patients reported angina when exercising to the same level. Exercise capacity on oral nicardipine treatment tended to increase whilst the ejection fraction response to exercise did not change. Thus, nicardipine was a potent vasodilator, which produced a marked reduction of systemic vascular resistance and left ventricular end diastolic pressure during exercise.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027147      PMCID: PMC1400788          DOI: 10.1111/j.1365-2125.1985.tb05159.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  New perspectives in the pharmacologic therapy of cardiac arrhythmias.

Authors:  B N Singh; J T Collett; C Y Chew
Journal:  Prog Cardiovasc Dis       Date:  1980 Jan-Feb       Impact factor: 8.194

2.  Reversible left-ventricular failure in angina pectoris.

Authors:  B Sharma; S H Taylor
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

3.  Haemodynamic effects of nifedipine in heart failure.

Authors:  S Klugmann; A Salvi; F Camerini
Journal:  Br Heart J       Date:  1980-04

4.  Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy.

Authors:  P Hanrath; D G Mathey; P Kremer; F Sonntag; W Bleifeld
Journal:  Am J Cardiol       Date:  1980-06       Impact factor: 2.778

5.  Improved exercise performance in persons with stable angina pectoris receiving diltiazem.

Authors:  K F Hossack; R A Bruce
Journal:  Am J Cardiol       Date:  1981-01       Impact factor: 2.778

6.  Hemodynamic effects of nifedipine during upright exercise in stable angina pectoris and either normal or severely impaired left ventricular function.

Authors:  G I Nelson; B Silke; R C Ahuja; S P Verma; M Hussain; S H Taylor
Journal:  Am J Cardiol       Date:  1984-02-01       Impact factor: 2.778

Review 7.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

8.  Increased exercise tolerance after oral diltiazem, a calcium antagonist, in angina pectoris.

Authors:  Y Koiwaya; M Nakamura; A Mitsutake; S Tanaka; A Takeshita
Journal:  Am Heart J       Date:  1981-02       Impact factor: 4.749

9.  Hemodynamic effects of nifedipine in congestive heart failure.

Authors:  S Matsumoto; T Ito; T Sada; M Takahashi; K M Su; A Ueda; F Okabe; M Sato; I Sekine; Y Ito
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  4 in total

1.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

2.  An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.

Authors:  B Silke; E Goldhammer; S K Sharma; S P Verma; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

3.  Aims of combination therapy--improved quality of life or better blood pressure control?

Authors:  D Maclean
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

Authors:  A Kuhn; J Carlsson; S Miketic; U Tebbe
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.